Cargando…
Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice
Our previous research demonstrated that soluble amyloid-β (Aβ)(42), elicits presynaptic glutamate release. We hypothesized that accumulation and deposition of Aβ altered glutamatergic neurotransmission in a temporally and spatially dependent manner. To test this hypothesis, a glutamate selective mic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467928/ https://www.ncbi.nlm.nih.gov/pubmed/32879385 http://dx.doi.org/10.1038/s41598-020-71587-6 |
_version_ | 1783578113985216512 |
---|---|
author | Hascup, Kevin N. Findley, Caleigh A. Sime, Lindsey N. Hascup, Erin R. |
author_facet | Hascup, Kevin N. Findley, Caleigh A. Sime, Lindsey N. Hascup, Erin R. |
author_sort | Hascup, Kevin N. |
collection | PubMed |
description | Our previous research demonstrated that soluble amyloid-β (Aβ)(42), elicits presynaptic glutamate release. We hypothesized that accumulation and deposition of Aβ altered glutamatergic neurotransmission in a temporally and spatially dependent manner. To test this hypothesis, a glutamate selective microelectrode array (MEA) was used to monitor dentate (DG), CA3, and CA1 hippocampal extracellular glutamate levels in 2–4, 6–8, and 18–20 month-old male AβPP/PS1 and age-matched C57BL/6J control mice. Starting at 6 months of age, AβPP/PS1 basal glutamate levels are elevated in all three hippocampal subregions that becomes more pronounced at the oldest age group. Evoked glutamate release was elevated in all three age groups in the DG, but temporally delayed to 18–20 months in the CA3 of AβPP/PS1 mice. However, CA1 evoked glutamate release in AβPP/PS1 mice was elevated at 2–4 months of age and declined with age. Plaque deposition was anatomically aligned (but temporally delayed) with elevated glutamate levels; whereby accumulation was first observed in the CA1 and DG starting at 6–8 months that progressed throughout all hippocampal subregions by 18–20 months of age. The temporal hippocampal glutamate changes observed in this study may serve as a biomarker allowing for time point specific therapeutic interventions in Alzheimer’s disease patients. |
format | Online Article Text |
id | pubmed-7467928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74679282020-09-03 Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice Hascup, Kevin N. Findley, Caleigh A. Sime, Lindsey N. Hascup, Erin R. Sci Rep Article Our previous research demonstrated that soluble amyloid-β (Aβ)(42), elicits presynaptic glutamate release. We hypothesized that accumulation and deposition of Aβ altered glutamatergic neurotransmission in a temporally and spatially dependent manner. To test this hypothesis, a glutamate selective microelectrode array (MEA) was used to monitor dentate (DG), CA3, and CA1 hippocampal extracellular glutamate levels in 2–4, 6–8, and 18–20 month-old male AβPP/PS1 and age-matched C57BL/6J control mice. Starting at 6 months of age, AβPP/PS1 basal glutamate levels are elevated in all three hippocampal subregions that becomes more pronounced at the oldest age group. Evoked glutamate release was elevated in all three age groups in the DG, but temporally delayed to 18–20 months in the CA3 of AβPP/PS1 mice. However, CA1 evoked glutamate release in AβPP/PS1 mice was elevated at 2–4 months of age and declined with age. Plaque deposition was anatomically aligned (but temporally delayed) with elevated glutamate levels; whereby accumulation was first observed in the CA1 and DG starting at 6–8 months that progressed throughout all hippocampal subregions by 18–20 months of age. The temporal hippocampal glutamate changes observed in this study may serve as a biomarker allowing for time point specific therapeutic interventions in Alzheimer’s disease patients. Nature Publishing Group UK 2020-09-02 /pmc/articles/PMC7467928/ /pubmed/32879385 http://dx.doi.org/10.1038/s41598-020-71587-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Hascup, Kevin N. Findley, Caleigh A. Sime, Lindsey N. Hascup, Erin R. Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice |
title | Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice |
title_full | Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice |
title_fullStr | Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice |
title_full_unstemmed | Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice |
title_short | Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice |
title_sort | hippocampal alterations in glutamatergic signaling during amyloid progression in aβpp/ps1 mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467928/ https://www.ncbi.nlm.nih.gov/pubmed/32879385 http://dx.doi.org/10.1038/s41598-020-71587-6 |
work_keys_str_mv | AT hascupkevinn hippocampalalterationsinglutamatergicsignalingduringamyloidprogressioninabppps1mice AT findleycaleigha hippocampalalterationsinglutamatergicsignalingduringamyloidprogressioninabppps1mice AT simelindseyn hippocampalalterationsinglutamatergicsignalingduringamyloidprogressioninabppps1mice AT hascuperinr hippocampalalterationsinglutamatergicsignalingduringamyloidprogressioninabppps1mice |